Innovations in Liquid Biopsy Techniques for Cancer Management

Liquid Biopsy Technologies Likely to Lead the Transformation of Cancer Profiling and Personalized Treatment Strategies

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

This research service encompasses a comprehensive analysis of minimally-invasive and non-invasive biopsy platforms that enable enhanced tumor profiling, treatment monitoring and precision oncology applications. This service primarily focuses on the use of circulating tumor DNA (ctDNA) circulating tumor cells (CTCs) and extracellular vesicles (EVs), derived from bio-fluids such as blood and urine, for molecular analysis across research and healthcare settings. This study also evaluates the technology, clinical, patent, and application landscapes prevalent across liquid biopsy settings, while providing valuable insights across its global technological impact and future perspectives.

Table of Contents

1.0 Executive Summary1.1 Research Scope1.2 Research Methodology1.2 Research Methodology (Continued)1.3 Key Findings2.0 Technology Snapshot and Overview2.1 Overview of Key Liquid Biopsy (LB) Markers2.2 Key Liquid Biopsy Markers Comprise Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) and Extracellular Vesicles (EVs)3.0 Technologies Analyzing ctDNA3.1 Next-Generation Sequencing Platforms Likely to Fuel ctDNA Analysis3.2 Overview of PCR-Based Technologies for ctDNA Analysis3.3 Next-Generation Sequencing Tools for ctDNA Assessment3.4 Emerging ctDNA Technologies Likely to Enable Comprehensive genome Profiling3.5 ctDNA Leads Profiling and Therapy Monitoring Applications in Clinical Trial Studies3.6 China Leads the Global Patent Landscape for ctDNA-based Technologies3.7 Research Funding in US for ctDNA-based Projects Exceed $50M in 2015-2016 Period3.8 ctDNA Biomarkers Studies Likely to Accelerate Disease and Treatment Profiling Applications3.9 Leveraging Epigenetic Tools across Cancer Diagnostics3.10 Enabling Personalized Management of Cancer4.0 Technologies Enabling CTC Detection4.1 Circulating Tumor Cells Enable Comprehensive Analysis of Cancer4.2 Cellular Analytics for CTCs Enable Prognostic Insights for Cancer4.3 Technologies Facilitating Molecular Analysis of CTCs Likely to Transform Cancer Management4.4 Emerging Use of Microfluidic and Imaging Technologies Enhance CTC Analysis4.5 China Leads the Global Patent Landscape for CTCs4.6 NIH funding for CTC-based Projects Exceeded $150 million during 2015-20164.7 CTCs Likely to Lead Disease Profiling, Treatment Profiling and Prognostic Applications across Several Cancers4.8 Combining ctDNA and CTC Analyses for Liquid Biopsy Assays4.9 US FDA Approved CTC Assay5.0 Technologies for Assessment of Extracellular Vesicles5.1 Exosomes Likely to Garner Growing Attention across Cancer Liquid Biopsy Applications5.2 Affinity Capture and Microfluidics techniques Likely to Enhance Exosome Isolation and Detection in the Near Future5.3 Advances across Proteomic and Nucleic Acid Assay Techniques Likely to Enhance Exosome Markers Detection5.4 North America Leads the Global Patent Landscape for Extracellular Vesicle-based Technologies5.5 US Research Funding for EV-based Technologies Exceeds $250 Million during 2015-20165.6 Exosomal Markers Likely to Lead Disease Profiling and Treatment Monitoring Applications5.7 Exosome-based Liquid Biopsy Assays for Precision Oncology5.8 Novel Platforms for Enhanced Isolation of EVs6.0 Impact Analysis and Future Perspectives6.1 Summary of Key Technology Drivers6.2 Technology Advancements and Rising Preference for Minimally Invasive Methods Likely to Fuel Liquid Biopsy Platforms6.3 Summary of Key Technology Challenges6.4 Enhancing Assay Accuracy and Clinical Utility of Biomarkers Constitute Key Challenges across Liquid Biopsy Tests6.5 Liquid Biopsy Platforms Likely to Transform Disease Profiling and Precision Medicine Applications7.0 Growth Opportunities and Companies to Action7.1 Growth Opportunity 1: ctDNA7.2 Growth Opportunity 2: CTCs7.3 Growth Opportunity 3: EVs7.4 Strategic Imperatives for Success and Growth 8.0 Appendix8.1 Key Contacts8.1 Key Contacts (continued)Legal Disclaimer9.0 The Frost & Sullivan Story9.1 The Frost & Sullivan Story9.2 Value Proposition: Future of Your Company & Career9.3 Global Perspective9.4 Industry Convergence9.5 360º Research Perspective9.6 Implementation Excellence9.7 Our Blue Ocean Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.